|
What's your broad perspective on the uptake of pharmacogenomics to-date as a drug development activity, and how significant do you think this is for the industry? First of all, we have long believed that pharmacogenomics is really the first application of the genomics revolution. In other words, the first key products that will come out of the whole genomics field will be in the form of molecular diagnostics, based on determining genetic variability in patient response to drugs. We believe the pharmaceutical industry is now moving rapidly to incorporate pharmacogenomics across drug development activities. For example, in most clinical trials, DNA is being isolated and stored, to be queried later against genetic markers identifying which patients are responding to drugs. |
